Ten stocks mirrored a lackluster performance in the broader market on Tuesday, posting hefty double-digit losses primarily due to disappointing earnings performance and a lower growth outlook for the rest of the year.
Meanwhile, the Nasdaq led the drop with 0.65 percent, followed by the S&P 500 at 0.49 percent, and the Dow Jones at 0.14 percent.
In this article, we name the 10 worst-performing stocks on Tuesday and detail the reasons behind their weak performance.
To compile the list, we focused on stocks with at least $2 billion in capitalization and more than 5 million shares in trading volume.
A man in long sleeves looking at stock market data. Photo by Tima Miroshnichenko on Pexels
10. Hims & Hers Health, Inc. (NYSE:HIMS)
Hims & Hers fell by 12.36 percent on Tuesday to close at $55.52 apiece as investors soured on lower-than-expected revenues in the second quarter of the year.
In its updated report, Hims & Hers Health, Inc. (NYSE:HIMS) said revenues increased by 73 percent to $544.8 million from $315.6 million in the same period last year, but missed the $552 million estimates by analysts.
Net income, on the other hand, more than tripled to $42.5 million from $13.3 million in the same period last year.
For the first six months, net income soared by 277 percent to $91.99 million from $24.42 million year-on-year, while revenues jumped by 90 percent to $1.13 billion from $593 million in the same comparable period.
For the third quarter, Hims & Hers Health, Inc. (NYSE:HIMS) is targeting to reach $570 million to $590 million in revenues, as well as $2.3 billion to $2.4 billion in the full-year period.
“It’s never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine,” said Hims & Hers Health, Inc. (NYSE:HIMS) co-founder and CEO Andrew Dudum.
9. IAC Inc. (NASDAQ:IAC)
IAC saw its share prices decline by 13.01 percent on Tuesday to close at $34.38 apiece as investors sold off positions following a mixed earnings performance and revenue miss in the second quarter of the year.
In an updated report, IAC Inc. (NASDAQ:IAC) said revenues in the second quarter declined by 7 percent to $586.9 million from $634.4 million in the same period last year. The figure was lower by 2.4 percent than the $601.35 million expected by analysts.
Meanwhile, the company swung to a net income attributable to shareholders of $211 million from a $142 million net loss in the same period last year.
In the first half, revenues decreased by 7.9 percent to $1.16 billion from $1.26 billion in the same comparable period, while net loss attributable to shareholders narrowed by 94 percent to $5.35 million from $97.2 million.
For full-year 2025, IAC Inc. (NASDAQ:IAC) targets to hit adjusted EBITDA of $247 million to $285 million, and total operating income of $82 million to $140 million.
8. Organon & Co. (NYSE:OGN)
Organon fell for a second day on Tuesday, shedding 13.13 percent to close at $8.4 apiece following a disappointing earnings performance in the second quarter of the year.
In its updated report, Organon & Co. (NYSE:OGN) said net income declined by 26 percent to $145 million from $195 million in the same period last year, while revenues dipped by 1 percent to $1.59 billion from $1.6 billion year-on-year.
“During the quarter, we paid down principal on our long-term debt and began implementing meaningful cost savings, which together set us on a path to achieve net leverage below 4.0x by the end of this year. We will aim to drive further improvement, with the goal of achieving net leverage of 3.5x or below by the end of 2026,” said Organon & Co. (NYSE:OGN) CEO Kevin Ali.
For full-year 2025, Organon & Co. (NYSE:OGN) has raised its revenue target to $6.275 billion to $6.375 billion, from the previous range of $6.125 billion to $6.325 billion.
It also declared a $0.02 cash dividend for each common share held as of August 15. The dividends are payable on September 11.
7. Shift4 Payments, Inc. (NYSE:FOUR)
Shift5 Payments fell back below the $100 territory on Tuesday, closing 15.43 percent lower at $86.43 apiece as investor sentiment was dampened by a disappointing earnings performance in the second quarter of the year.
In its earnings release, Shift4 Payments, Inc. (NYSE:FOUR) said net income attributable to shareholders declined by 37.5 percent to $24.5 million from $39.2 million in the same period last year. Gross revenues, however, increased by 16.8 percent to $966.2 million from $827 million year-on-year. Analysts expected the company to post $982.95 million in revenues.
Attributable net income also decreased by 31 percent to $41.2 million from $59.8 million, while gross revenues grew by 20 percent to $1.8 billion from $1.5 billion year-on-year.
For full-year 2025, Shift4 Payments, Inc. (NYSE:FOUR) targets to hit $1.965 billion to $2.035 billion in revenues, or 45-50 percent higher year-on-year.
In the third quarter alone, gross revenues are expected to hit $590 million.
6. Alight, Inc. (NYSE:ALIT)
Alight Inc. declined by 18.32 percent on Tuesday to end at $4.19 apiece following a disappointing earnings performance in the second quarter of the year.
In its updated report, Alight, Inc. (NYSE:ALIT) said it swung to an attributable net loss of $1.07 billion in the second quarter of the year from a $23 million attributable net income in the same period last year. Revenues dipped by 1.8 percent to $528 million from $538 million year-on-year due to lower project revenue and net commercial activity.
For the first half, attributable net loss widened by 1,106 percent to $1.098 billion from $91 million in the same period last year, primarily driven by the $983 million non-cash goodwill impairment charge related to its Health Solutions reporting unit. Revenues dipped by 2 percent to $1.076 billion from $1.097 billion year-on-year.
For full-year 2025, the revenue target was lowered to a range of $2.282 billion to $2.329 billion from the $2.318 billion to $2.388 billion as guided previously.
“We feel good about the operational levers within our control and are tracking to another strong year of client retention rates, though we refined our top-line forecast due to deals taking longer to close in the current environment which is temporarily delaying planned growth. Our pipeline remains strong, particularly for deals in the later stages, and we continue to see good progress with prospective clients,” said Alight, Inc. (NYSE:ALIT) CEO Dave Guilmette.
5. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)
Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an experimental pain medicine.
The company dropped as low as 21 percent to $373.2 before a slight uptick to close the day just down by 20.6 percent at $374.98 apiece.
In a statement, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said that its clinical trial for VX-993 for the Treatment of Acute Pain “did not result in a statistically significant improvement” to the enrolled patients.
“Based on these results, Vertex will not progress VX-993 into pivotal development as monotherapy in acute pain,” it said.
The termination overshadowed the company’s impressive earnings performance in the second quarter and first half of the year.
During the quarter, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) swung to a net income of $1.03 billion from a $3.593 billion net loss in the same period last year. Total revenues grew by 12 percent to $2.96 billion from $2.64 billion year-on-year.
In the first half, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) swung to a net profit of $1.68 billion from a $2.49 billion net loss year-on-year, while total revenues grew by 8 percent to $5.73 billion from $5.3 billion.
4. Kyndryl Holdings, Inc. (NYSE:KD)
Kyndryl Holdings fell by 21 percent on Tuesday to close at $28.94 apiece as investors soured on the disappointing earnings performance in the first quarter of fiscal year 2026.
In its updated report, Kyndryl Holdings, Inc. (NYSE:KD) said revenues during the period finished flat year-on-year at $3.7 billion, falling short of its $3.83 billion forecast.
However, net income expanded by 409 percent to $56 million from $11 million in the same period last year.
For the full fiscal year of 2026, Kyndryl Holdings, Inc. (NYSE:KD) said it was targeting an adjusted EBITDA margin of approximately 18 percent, representing a year-over-year increase of approximately 130 basis points.
“Our first quarter reflected steady progress across key growth areas of our business, with contributions from Kyndryl Consult, hyperscaler-related activity, scope expansions, and productivity gains. Our expertise in mission-critical technology and our unique operational capabilities, including Kyndryl Bridge, are helping customers innovate and create new growth opportunities for Kyndryl,” said Kyndryl Holdings, Inc. (NYSE:KD) Chairman and CEO Martin Schroeter.
3. Oddity Tech Ltd. (NASDAQ:ODD)
Oddity Tech fell by 22.04 percent on Tuesday to close at $57.72 apiece as investors appeared to have taken profits to take advantage of last week’s gains.
The decline followed the official release of Oddity Tech Ltd.’s (NASDAQ:ODD) second-quarter earnings performance, suggesting that investors may have already priced in the news.
In its updated report, Oddity Tech Ltd. (NASDAQ:ODD) said that net income increased by 8 percent to $49.28 million from $45.49 million in the same period last year.
Net revenues increased by 25 percent to $241 million from $192.77 million year-on-year.
In the first half, net income increased by 11 percent to $87 million from $78 million, while revenues grew by 26 percent to $509 million from $404 million.
Encouraged by the strong results, Oddity Tech Ltd. (NASDAQ:ODD) raised its revenue growth outlook for full-year 2025 to $799 million to $804 million from the $790 million to $798 million as previously guided.
For the third quarter alone, the company said revenues were targeted to hit $144 million to $146 million.
2. Inspire Medical Systems, Inc. (NYSE:INSP)
Inspire Medical nosedived by 32.35 percent on Tuesday to end at $87.91 apiece as investors unloaded portfolios following a disappointing earnings performance in the second quarter of the year, coupled with a lower growth outlook for the full year.
This followed the company’s swing to a $3.59 million net loss in the second quarter of the year, reversing a $9.8 million net income in the same period last year.
Revenues, however, jumped by 10.7 percent to $217 million from $195.88 million in the same comparable period.
In the first half, Inspire Medical Systems, Inc. (NYSE:INSP) said it widened its net loss by 183 percent to $600 million from $212 million, while revenues grew by 16 percent to $418 million from $360 million.
Commenting on the company’s performance, Inspire Medical Systems, Inc. (NYSE:INSP) Chairman and CEO Tim Herbert believed that operational headwinds were just temporary and that actions are underway to address them.
For full-year 2025, the company expects revenues to now settle between $900 million and $910 million, lower than the $940 million to $955 million expected previously.
1. BellRing Brands, Inc. (NYSE:BRBR)
BellRing extended its losing streak to a fifth consecutive day on Tuesday, slashing 32.55 percent to close at $36.18 apiece after posting disappointing earnings and a lower growth outlook for full-year 2025.
In its updated report, BellRing Brands, Inc. (NYSE:BRBR) said net income in the third quarter of fiscal year 2025 fell by 71.5 percent to $21 million from $73.7 million in the same period last year, while revenues grew by 6 percent to $547.5 million from $515.4 million year-on-year.
Net income in the nine-month period also declined by 10.4 percent to $156.6 million from $174.8 million in the same comparable period. Net sales amounted to $1.67 billion, higher by 15.8 percent than the $1.44 billion year-on-year.
For the full year 2025, BellRing Brands, Inc. (NYSE:BRBR) lowered its net sales growth outlook to a range of $2.28 billion to $2.32 billion, as well as adjusted EBITDA of $480 million to $490 million.
“Looking ahead, our fiscal year 2025 outlook remains solid and intact, despite minor shipment timing shifts between the third and fourth quarters. Our leading mainstream brands continue to resonate with consumers, and we remain confident in the long-term trajectory for BellRing,” said BellRing Brands, Inc. (NYSE:BRBR) CEO Darcy Davenport.
While we acknowledge the potential of BRBR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BRBR and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
